Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection

ACTG 068

Donna Mildvan, Yiannis Bassiakos, Marcia L. Zucker, Newton Hyslop, Susan E. Krown, Henry S. Sacks, James Zachary, Josephine Paredes, W. Jeffrey Fessel, Frank Rhame, Francoise Kramer, Margaret A Fischl, Bernard Poiesz, Kenneth Wood, Ruth M. Ruprecht, John Kim, Sidney E. Grossberg, Patricia Kasdan, Peter Bergé, Ann Marshak & 1 others Carla Pettinelli

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Thirty-four subjects with symptomatic HIV-1 infection, p24 antigenaemia, and CD4 cell counts > 200/mm3 were randomly assigned to receive treatment with either zidovudine (ZDV) orally, interferon-alpha (IFN-α) subcutaneously, or both at respective low (200 mg ZDV/2 million international units IFN-α (MIU)), middle (400 mg/4 MIU) or high (600 mg/6 MIU) daily dose levels for 12 weeks. Thereafter, all patients received combination therapy at the initially assigned dose level to a total of 96 weeks. This design permitted analysis by the combination index (CI) method, which demonstrated antiretroviral synergy between ZDV and IFN-α with respect to p24 antigen suppression. Over the first 12 weeks, combination therapy was acceptably tolerated, more so than IFN-α monotherapy, and it was significantly more active in suppressing antigenaemia than either of the monotherapies. Similarly, the high-dose combination was the most active dose level over weeks 12 to 96. Combination ZDV/IFN-α. at the optimal dose level defined by this trial merits further study. In addition, the CI design strategy employed here may be useful for the investigation of new antiretroviral combinations.

Original languageEnglish
Pages (from-to)77-88
Number of pages12
JournalAntiviral Therapy
Volume1
Issue number2
StatePublished - Dec 1 1996

Fingerprint

Zidovudine
Interferon-alpha
HIV Infections
HIV-1
CD4 Lymphocyte Count
Therapeutics
Antigens

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mildvan, D., Bassiakos, Y., Zucker, M. L., Hyslop, N., Krown, S. E., Sacks, H. S., ... Pettinelli, C. (1996). Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068. Antiviral Therapy, 1(2), 77-88.

Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection : ACTG 068. / Mildvan, Donna; Bassiakos, Yiannis; Zucker, Marcia L.; Hyslop, Newton; Krown, Susan E.; Sacks, Henry S.; Zachary, James; Paredes, Josephine; Fessel, W. Jeffrey; Rhame, Frank; Kramer, Francoise; Fischl, Margaret A; Poiesz, Bernard; Wood, Kenneth; Ruprecht, Ruth M.; Kim, John; Grossberg, Sidney E.; Kasdan, Patricia; Bergé, Peter; Marshak, Ann; Pettinelli, Carla.

In: Antiviral Therapy, Vol. 1, No. 2, 01.12.1996, p. 77-88.

Research output: Contribution to journalArticle

Mildvan, D, Bassiakos, Y, Zucker, ML, Hyslop, N, Krown, SE, Sacks, HS, Zachary, J, Paredes, J, Fessel, WJ, Rhame, F, Kramer, F, Fischl, MA, Poiesz, B, Wood, K, Ruprecht, RM, Kim, J, Grossberg, SE, Kasdan, P, Bergé, P, Marshak, A & Pettinelli, C 1996, 'Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068', Antiviral Therapy, vol. 1, no. 2, pp. 77-88.
Mildvan D, Bassiakos Y, Zucker ML, Hyslop N, Krown SE, Sacks HS et al. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068. Antiviral Therapy. 1996 Dec 1;1(2):77-88.
Mildvan, Donna ; Bassiakos, Yiannis ; Zucker, Marcia L. ; Hyslop, Newton ; Krown, Susan E. ; Sacks, Henry S. ; Zachary, James ; Paredes, Josephine ; Fessel, W. Jeffrey ; Rhame, Frank ; Kramer, Francoise ; Fischl, Margaret A ; Poiesz, Bernard ; Wood, Kenneth ; Ruprecht, Ruth M. ; Kim, John ; Grossberg, Sidney E. ; Kasdan, Patricia ; Bergé, Peter ; Marshak, Ann ; Pettinelli, Carla. / Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection : ACTG 068. In: Antiviral Therapy. 1996 ; Vol. 1, No. 2. pp. 77-88.
@article{282d3fa985704c58add3df457a60fedf,
title = "Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068",
abstract = "Thirty-four subjects with symptomatic HIV-1 infection, p24 antigenaemia, and CD4 cell counts > 200/mm3 were randomly assigned to receive treatment with either zidovudine (ZDV) orally, interferon-alpha (IFN-α) subcutaneously, or both at respective low (200 mg ZDV/2 million international units IFN-α (MIU)), middle (400 mg/4 MIU) or high (600 mg/6 MIU) daily dose levels for 12 weeks. Thereafter, all patients received combination therapy at the initially assigned dose level to a total of 96 weeks. This design permitted analysis by the combination index (CI) method, which demonstrated antiretroviral synergy between ZDV and IFN-α with respect to p24 antigen suppression. Over the first 12 weeks, combination therapy was acceptably tolerated, more so than IFN-α monotherapy, and it was significantly more active in suppressing antigenaemia than either of the monotherapies. Similarly, the high-dose combination was the most active dose level over weeks 12 to 96. Combination ZDV/IFN-α. at the optimal dose level defined by this trial merits further study. In addition, the CI design strategy employed here may be useful for the investigation of new antiretroviral combinations.",
author = "Donna Mildvan and Yiannis Bassiakos and Zucker, {Marcia L.} and Newton Hyslop and Krown, {Susan E.} and Sacks, {Henry S.} and James Zachary and Josephine Paredes and Fessel, {W. Jeffrey} and Frank Rhame and Francoise Kramer and Fischl, {Margaret A} and Bernard Poiesz and Kenneth Wood and Ruprecht, {Ruth M.} and John Kim and Grossberg, {Sidney E.} and Patricia Kasdan and Peter Berg{\'e} and Ann Marshak and Carla Pettinelli",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "1",
pages = "77--88",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "2",

}

TY - JOUR

T1 - Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection

T2 - ACTG 068

AU - Mildvan, Donna

AU - Bassiakos, Yiannis

AU - Zucker, Marcia L.

AU - Hyslop, Newton

AU - Krown, Susan E.

AU - Sacks, Henry S.

AU - Zachary, James

AU - Paredes, Josephine

AU - Fessel, W. Jeffrey

AU - Rhame, Frank

AU - Kramer, Francoise

AU - Fischl, Margaret A

AU - Poiesz, Bernard

AU - Wood, Kenneth

AU - Ruprecht, Ruth M.

AU - Kim, John

AU - Grossberg, Sidney E.

AU - Kasdan, Patricia

AU - Bergé, Peter

AU - Marshak, Ann

AU - Pettinelli, Carla

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Thirty-four subjects with symptomatic HIV-1 infection, p24 antigenaemia, and CD4 cell counts > 200/mm3 were randomly assigned to receive treatment with either zidovudine (ZDV) orally, interferon-alpha (IFN-α) subcutaneously, or both at respective low (200 mg ZDV/2 million international units IFN-α (MIU)), middle (400 mg/4 MIU) or high (600 mg/6 MIU) daily dose levels for 12 weeks. Thereafter, all patients received combination therapy at the initially assigned dose level to a total of 96 weeks. This design permitted analysis by the combination index (CI) method, which demonstrated antiretroviral synergy between ZDV and IFN-α with respect to p24 antigen suppression. Over the first 12 weeks, combination therapy was acceptably tolerated, more so than IFN-α monotherapy, and it was significantly more active in suppressing antigenaemia than either of the monotherapies. Similarly, the high-dose combination was the most active dose level over weeks 12 to 96. Combination ZDV/IFN-α. at the optimal dose level defined by this trial merits further study. In addition, the CI design strategy employed here may be useful for the investigation of new antiretroviral combinations.

AB - Thirty-four subjects with symptomatic HIV-1 infection, p24 antigenaemia, and CD4 cell counts > 200/mm3 were randomly assigned to receive treatment with either zidovudine (ZDV) orally, interferon-alpha (IFN-α) subcutaneously, or both at respective low (200 mg ZDV/2 million international units IFN-α (MIU)), middle (400 mg/4 MIU) or high (600 mg/6 MIU) daily dose levels for 12 weeks. Thereafter, all patients received combination therapy at the initially assigned dose level to a total of 96 weeks. This design permitted analysis by the combination index (CI) method, which demonstrated antiretroviral synergy between ZDV and IFN-α with respect to p24 antigen suppression. Over the first 12 weeks, combination therapy was acceptably tolerated, more so than IFN-α monotherapy, and it was significantly more active in suppressing antigenaemia than either of the monotherapies. Similarly, the high-dose combination was the most active dose level over weeks 12 to 96. Combination ZDV/IFN-α. at the optimal dose level defined by this trial merits further study. In addition, the CI design strategy employed here may be useful for the investigation of new antiretroviral combinations.

UR - http://www.scopus.com/inward/record.url?scp=17144467145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144467145&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 77

EP - 88

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 2

ER -